Anderson, John
Levy, Donald S.
Lumry, William
Koochaki, Patricia
Lanar, Sally
Henry Li, H.
Funding for this research was provided by:
CSL Behring
Article History
Received: 17 June 2020
Accepted: 1 May 2021
First Online: 27 June 2021
Declarations
:
: The study was exempted from ethics approval by the Chesapeake (currently, Advarra) IRB (Columbia, Maryland).
: Written informed consent was obtained from all patients prior to being interviewed.
: J Anderson is a PI, consultant, and speaker for CSL Behring, Shire/Takeda, and Pharming and a PI for BioCryst. W Lumry is a consultant for Adverum, Attune, BioCryst, CSL Behring, Kalvista, Pharming, and Takeda; a speaker for CSL Behring, Pharming, and Takeda; and has received research grants from BioCryst, CSL Behring, Pharming, and Takeda. DS Levy has served as a consultant, speaker, and has received research grants from CSL Behring; he has served as a consultant for BioCryst; he has served as a speaker for Takeda. P Koochaki and S Lanar are employees of ICON plc, which received funding through Churchill Communications to conduct this study on behalf of the funding sponsor, CSL Behring. HH Li has conducted research with and has served a consultant/received speakers’ fees from Shire/Takeda, BioCryst, and CSL Behring; he has served as a consultant/received speakers’ fees from Pharming.